Table 3.
Univariate and multivariate cox regression analysis for 3-year overall survival rate.
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR(95% CI) | p | HR(95% CI) | p | ||
| Age (years) | ≤60 | 1 | 0.216 | 1 | 0.581 |
| >60 | 0.69 (0.39–1.24) | 0.83 (0.43–1.60) | |||
| Pre-treatment PSA (ng/mL) | ≤20 | 1 | 0.007 | 1 | 0.346 |
| >20 | 2.96 (1.34–6.57) | 1.05 (0.54–5.66) | |||
| Clinical stage | I and II | 1 | 0.006 | 1 | 0.039 |
| III and IV | 3.34 (1.42–7.84) | 2.65 (1.78–4.19) | |||
| GS | <8 | 1 | 0.003 | 1 | 0.008 |
| ≥8 | 2.54 (1.37–4.70) | 1.88 (3–7.11) | |||
| TE | ≤50% | 1 | 0.103 | 1 | 0.801 |
| >50% | 1.67 (0.90–3.08) | 0.92 (0.49–1.71) | |||
| PNI | No | 1 | 0.001 | 1 | 0.176 |
| Yes | 0.37 (0.21–0.67) | 0.63 (0.32–1.23) | |||
| LVI | No | 1 | 0.0005 | 1 | 0.002 |
| Yes | 0.25 (0.14–0.45) | 0.37 (0.18–0.69) | |||
GS: Gleason score, PSA: prostatic specific antigen, TE: tumour extent, PNI: perineural invasion, LVI: lymphovascular invasion, CI: confidence interval, HR: hazard ratio. Reference HR = 1.